Specific and selective If inhibition: Expected clinical benefits from pure heart rate reduction in coronary patients

European Heart Journal, Supplement

Volumn 7, Issue H, 2005, Pages

  Ferrari, Roberto ^a,b   Campo, Gianluca ^a   Gardini, Elisa ^a   Pasanisi, Giovanni ^a   Ceconi, Claudio ^a,b  

^a UNIVERSITY OF FERRARA   (Italy)

^b IRCCS   (Italy)

Author keywords

Cardiovascular risk; Cellular energetic needs; Heart rate; If current; Ivabradine

Indexed keywords

ALINIDINE; ANTIANGINA PECTORIS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; IVABRADINE; ZATEBRADINE;

CARDIOVASCULAR DISEASE; ENERGY EXPENDITURE; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE PERFUSION; HEART RATE; HUMAN; ION CURRENT; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINUS NODE;

EID: 24744465635     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sui048     Document Type: Review

References (36)

1. Dyer AR, Persky V, Stamler J et al. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol 1980;112:736-749.
2. Kannel WB, Kannel C, Paffenbarger RS Jr et al. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987;113:1489-1494.
3. Gillum RF, Makus DM, Feldman JJ. Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study. Am Heart J 1991;121:172-177.
4. Diaz A, Bourassa MG, Guertin MC et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005;26:967-974.
5. Kjekshus J. Importance of heart-rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986;57:43F-49F.
6. Kjekshus J, Gullestad L. Heart rate as a therapeutic target in heart failure. Eur Heart J 1999;1(Suppl. H):H64-H69.
7. Simonsen S, Ihlen H, Kjekshus JK. Haemodynamic and metabolic effects of timolol (Blocadren) on ischaemic myocardium. Acta Med Scand 1983;213:393-398.
8. f Inhibition in Cardiovascular Disease. London: Lippincott, Williams and Wilkins; 2003. p1-134.
9. Brown HF, DiFrancesco D, Noble SJ. How does adrenaline accelerate the heart? Nature 1979;280:235-236.
10. f current inhibition with ivabradine. Drugs 2004;64:1757-1765.
11. Ogiwara Y, Furukawa Y, Akahane K et al. Bradycardic effects of AQ-A 39 (falipamil) in situ and in isolated, blood-perfused dog hearts. Comparison with alinidine and verapamil. Jpn Heart J 1988;29:849-861.
12. Thollon C, Bidouard JP, Cambarrat C et al. Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S16257. Eur J Pharmacol 1997;339:43-51.
13. f channels by ivabradine. J Gen Physiol 2002;120:1-13.
14. Bois P, Bescond J, Renaudon B et al. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol 1996;118:1051-1057.
15. Levine HJ. Rest heart rate and life expectancy. J Am Coll Cardiol 1997;30:1104-1106.
16. Azbel MY. Universal biological scaling and mortality. Proc Natl Acad Sci USA 1994;91:12453-12457.
17. Spector WS. Handbook of Biological Data. Philadelphia: WB Saunders; 1956.
18. Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol 1986;250:H1145-H1149.
19. Schmidt-Nielsen K. Animal Physiology: Adaptation and Environment. New York: Cambridge University Press; 1975. p135.
20. Coburn AF, Grey RM, Rivera SM. Observations on the relation of heart rate, life span, weight and mineralization in the digoxin-treated A/J mouse. Johns Hopkins Med J 1971;128:169-193.
21. Hjalmarson A, Gilpin E, Kjekshus J et al. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 1990;65:547-553.
22. Gillman M, Kannel W, Belanger A, D'Agostino R. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J 1993;125:1148-1154.
23. Opie LH. The Heart: Physiology and Metabolism. New York: Raven Press; 1991.
24. Balaban RS. Regulation of oxidative phosphorylation in the mammalian cell. Am J Physiol 1990;258:C377-C389.
25. Kjekshus J. Importance of heart rate in determining beta-blocker efficacy in acute and long-term myocardial infarction intervention trials. Am J Cardiol 1986;57:43F-49F.
26. The Multicenter Diltiazem Postinfarction Trial Research Group. Effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-392.
27. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II-DAVIT II). Am J Cardiol 1990;66:779-785.
28. Furberg CD, Hawkins CM, Lichstein E for the Beta-Blocker Heart Attack Trial Study Group. Effect of propranolol in postinfarction patients with mechanical or electrical complications. Circulation 1984;69:761-765.
29. Simon L, Ghaleh B, Puybasset L et al. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther 1995;275:659-666.
30. Ferrari R, Cargnoni A, Matrina P et al. Anti-ischaemic effect of Ivabradine in isolated rabbit hearts: modulation of cardiac metabolism. Cardiovasc Drugs Ther 2005, in press.
31. Monnet X, Colin P, Ghaleh B et al. Heart rate reduction during exercise-induced myocardial ischemia and stunning. Eur Heart J 2004;25:579-586.
32. f current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004;109:1674-1679.
33. Jondeau G, Korewicki J, Vasiliauskas D. Effect of ivabradine in patients with left ventricular systolic dysfunction and coronary artery disease. (Abstract 2637) Eur Heart J Suppl 2004;25(Abstract suppl):451.
34. Heidland UE, Stauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001;104:1477-1482.
35. f inhibitor, in stable angina. A randomised, double-blind, multicentered, placebo-controlled trial. Circulation 2003;107:817-823.
36. f inhibitor: efficacy and safety in stable angina. Eur Heart J Suppl 2003;5(Suppl. G):G36-G45.